-+ 0.00%
-+ 0.00%
-+ 0.00%
Bristol Myers Squibb's KarXT shows improvement in Alzheimer's psychosis symptoms in open-label Phase 3 studies
Share
Listen to the news
Bristol Myers Squibb's KarXT shows improvement in Alzheimer's psychosis symptoms in open-label Phase 3 studies
  • Bristol Myers Squibb presented preliminary Phase 3 data showing KarXT improved hallucinations, delusions and overall disease severity in Alzheimer's-associated psychosis.
  • Results from ADEPT-1's 12-week open-label period and ADEPT-3's 52-week extension were presented at the Clinical Trials on Alzheimer's Disease Conference.
  • KarXT was generally well tolerated across both studies, with no new safety signals identified.
  • The findings reflect descriptive analyses of open-label treatment; the ADEPT trials remain ongoing, with double-blind results still blinded.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20261117573732) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending